Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Reply New Message

Back To Forum List View

brentie98

Rank: President [?]

Points: 5496 [?]

Votes: 21 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

MannKind (MNKD) Affinity Trials Should be Low Risk, But Afrezza Approval Not Gua

posted on Aug 13, 2013 10:29AM

MannKind (MNKD) Affinity Trials Should be Low Risk, But Afrezza Approval Not Guaranteed - Analyst

Upcoming MannKind Corp. (Nasdaq: MNKD) Affinity Phase 1/2 trials should be a low risk event for investors.

Cowen's Simos Simeonidis commented today that there are fairly high chances of being positive, though the analyst is still cautious on Afrezza's chances of receiving FDA approval

MannKind would also need a commercial partner, but many potential pharmaceutical partners and investors are still skeptical about the need for inhaled insulin.

Cowen has MannKind at Market Perform and thinks the company is fully valued at $2.5 billion. Shares are down 1.9 percent early.

For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here.

Shares of MannKind closed at $7.47 last Friday, with a 52 week range of $1.82-$8.33.

http://www.streetinsider.com/Analyst+Comments/MannKind+%28MNKD%29+Affinity+Trials+Should+be+Low+Risk%2C+But+Afrezza+Approval+Not+Guaranteed+-+Analyst/8590927.html

1 Recommendations

Re: MannKind (MNKD) Affinity Trials Should be Low Risk, But Afrezza Approval Not Gua